← Back

XtalPi Holdings Limited

XtalPi Holdings Limited operates as a research platform company in Mainland China, the United States, and internationally. The company offers XmartChem, an intelligent synthesis workstation which automates the chemical synthesis process; ChemPlus, desktop solid dispensing device; PatSight, an optical chemical structure extraction tool for patents; and XFEP, a software for rapid FEP calculations using cloud computing. It also provides XMolGen, a generative chemistry tool; and drug discovery solutions, such as hit discovery, hit or lead optimization, and biology capabilities, as well as PepiX, which generates stable peptides. In addition, the company offers discovery chemistry solutions, including automation-aided chemical synthesis and focused library; and XtalGazer, a solid-state research solution. It has a strategic collaboration with Pfizer to co-build an AI-driven molecular simulation research and development platform; DoveTree to develop therapeutics designed for multiple difficult-to-drug targets; and strategic partnership with an international biopharmaceutical company to develop oral small molecule therapeutics for a GPCR target. The company was formerly known as QuantumPharm Inc. and changed its name to XtalPi Holdings Limited in December 2024. XtalPi Holdings Limited was founded in 2015 and is headquartered in Shenzhen, China.

Price · split & dividend adjusted
News & notes moving 2228.HK
Biotech & Genomic Medicine▼

XtalPi Holdings Reports 2026 Interim Results

XtalPi Holdings announced its 2026 interim results, reporting revenue of RMB393.6 million, down from RMB517.1 million a year earlier due to a high base from a prior upfront payment. Excluding that impact, revenue rose 73.8% year on year, with AI4S Intelligent Solutions revenue up 136.4% to RMB193.5 million. The company recorded a net loss of RMB224.9 million and an adjusted net loss of RMB105.5 million, while R&D expenses increased 66.0% year on year. As of June 30, 2026, XtalPi had a total cash balance of RMB8,671.2 million. The company also highlighted three clinical-stage pipelines, more than 10 IND-approved or IND-preparation programs, and a strategic AI drug discovery collaboration with a total potential value exceeding US$400 million.
2228.HK ▼
Biotech & Genomic Medicine
PR Newswire·7dRead more ▾
Biotech & Genomic Medicine▲

Generative AI in Pharmaceutical Market to Reach $9.36 Billion by 2030

The generative AI in pharmaceutical market is projected to grow from $2.43 billion in 2025 to $9.36 billion by 2030, at a compound annual growth rate of 30.9%. The market is expected to reach $3.19 billion in 2026, driven by increased R&D investments, rising chronic diseases, and AI adoption in early-stage drug discovery. A key growth driver is the rise of personalized medicine, with 16 novel personalized therapies approved by the FDA in 2023, up from six the previous year. Leading companies such as Pfizer, Johnson & Johnson, and Roche are active in the space, while Nvidia launched generative AI microservices for drug discovery in March 2024 and Eli Lilly partnered with XtalPi to explore chemical spaces for drug candidates. North America was the largest regional market in 2025, and the report covers global regions including Asia-Pacific, Europe, and the Americas.
NVDA ▲2228.HK ▲LLY ▲ROP.SW ▲
Biotech & Genomic Medicine ▲Artificial Intelligence ▲
GlobeNewswire·48dRead more ▾
© 2026 MarketDXAsset